No Data
Clearmind Medicine Expands Global IP Portfolio With Hong Kong Patent Filing
Clearmind Medicine Expends Global IP Portfolio With Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‐Billion‐Dollar PTSD Therapeutics Market
Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction
Express News | Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of Its Psychedelic-Based Neuroplastogen Meai
Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of Its Psychedelic-Based Neuroplastogen MEAI
CORRECTION: Clearmind Medicine Shares Are Trading Lower.